Pfizer CEO Acquires $601 in Phantom Stock Units via Comp Plan
PFIZER INC
Subscribe to track PFE
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Pfizer CEO Acquires $601 in Phantom Stock Units
Company: PFIZER INC (PFE) Form: 4 | Filed: 2025/11/17 Significance: Low
Insider: BOURLA ALBERT Title: Chairman & CEO | Relationship: Director, Officer
Transaction: • Type: Grant • Shares: 24 • Price: $25.06 • Value: $601 • Owned After: 743,548 Phantom Stock Units
Key Insight: This is a routine, de minimis acquisition of phantom stock units under a deferred compensation plan, carrying no market significance.
Market Context: The transaction value is negligible, representing less than 0.000001% of Pfizer's $142.48B market capitalization.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: PFIZER INC (PFE)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Chairman & CEO, Albert Bourla, acquired a nominal number of phantom stock units as part of a standard compensation plan.
- Market Impact: None. The transaction is immaterial in both size and nature.
Company Information
| Field | Value |
|---|---|
| Company | PFIZER INC |
| Ticker Symbol | PFE |
| CIK | 0000078003 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | BOURLA ALBERT |
| CIK | 0001595703 |
| Title/Position | Chairman & CEO |
| Relationship | Director, Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-14 |
| Transaction Code | A (Grant, award, or other acquisition) |
| Security Type | Phantom Stock Units SSP |
| Shares Involved | 24 |
| Price Per Share | $25.06 |
| Total Value | $601.44 |
| Shares Owned After | 743,548 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $601.44 |
| % of Market Cap | <0.00001% |
| Shares Transacted | 24 |
| % of Shares Outstanding | <0.00001% |
| Post-Transaction Ownership | 743,548 units (approx. 0.013% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a mega-cap company like Pfizer with a market capitalization of $142.48 billion, a transaction valued at approximately $600 is financially insignificant and represents a rounding error.
- Ownership Concentration: The CEO's total holding of phantom stock units remains a very small fraction (0.013%) of the total shares outstanding. This transaction does not materially alter that concentration.
- Dilution Impact: The acquisition of 24 share equivalents has a negligible, near-zero dilution impact on the 5.68 billion shares outstanding.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is a routine, automated acquisition under a compensation plan. It is not a discretionary trade and provides no new information to the market.
Volume & Sentiment
- Expected Volume Impact: None. The transaction is too small to have any effect on trading volume.
- Sentiment Indicator: Neutral. This filing is purely administrative and does not signal any bullish or bearish sentiment from the insider.
Additional Context
Transaction Notes
- Special Circumstances: The units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These are cash-settled upon separation from service, as noted in the filing's footnotes.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.